Alvotech (ALVO)

$4.90 -0.10 (-2.00%)
Market Cap 1.51B
Revenue (ttm) 489.68M
Net Income (ttm) -231.86M
EPS (ttm) N/A
PE Ratio 22.30
Forward PE 10.48
Profit Margin -47.35%
Debt to Equity Ratio -6.36
Volume 769,000
Avg Vol 665,822
Day's Range N/A - N/A
Shares Out 301.48M
Stochastic %K 25%
Beta 0.11
Analysts Sell
Price Target $8.60

Company Profile

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosim...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Address:
9, Rue de Bitbourg, Luxembourg, Luxembourg
LIKEAG6
LIKEAG6 Jan. 3 at 1:37 AM
$ALVO Does anybody here know what this means? https://ml-eu.globenewswire.com/Resource/Download/1fef1de4-9efb-4061-90cf-24118cf4c963
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 31 at 8:32 PM
$ALVO RSI: 41.78, MACD: -0.1703 Vol: 0.31, MA20: 5.18, MA50: 5.71 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
GoldenStripe
GoldenStripe Dec. 30 at 2:46 AM
$ALVO
1 · Reply
scholar9
scholar9 Dec. 26 at 1:47 PM
$AMZN premarket quick take — volume > price $AMZN is trading around $232.1–232.4 premarket with ~200K matched premarket shares (30-day avg premarket vol ~674K). Today’s premarket volume is materially below average, so price moves lack strong conviction. Price sits above the 50-day MA (~$229) → medium-term bias still mildly bullish but unconfirmed. Trade note: wait for opening-volume confirmation (first 5–30 minutes) before chasing a breakout. Short-term support ~$229 (50-day MA); major support ~$216 (200-day MA). Watch ~$235 for a volume-confirmed near-term breakout; long-term resistance sits at the 52-wk high $258.60.with notice👉@scholar9 $AAOI $RCAT $DPRO $ALVO (Info/TA only — not financial advice)
0 · Reply
IntelligenceInsider
IntelligenceInsider Dec. 26 at 1:33 PM
$ALVO Risk appetite is present but conditioned on validation. Governance alignment should reduce uncertainty over time. Risk compresses once delivery patterns become predictable. Upside remains tied to tangible progress, not assumptions.
0 · Reply
briefingcom
briefingcom Dec. 19 at 1:30 PM
$ALVO: Alvotech and $TEVA secure U.S. settlement date for AVT06, a proposed biosimilar to Eylea https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20251219050530ALVO&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
Wences
Wences Dec. 18 at 2:09 PM
$ALVO Wessman has killed the stock with the bond offering.
1 · Reply
www_larval_com
www_larval_com Dec. 16 at 5:12 PM
Lookie here $ALVO has shot 9% higher to 0% (~600Kv) moments ago, follow for more volatility.
0 · Reply
JarvisFlow
JarvisFlow Dec. 9 at 3:15 PM
Barclays updates rating for Alvotech ( $ALVO ) to Underweight, target set at 5.
1 · Reply
Muhammediceland
Muhammediceland Dec. 8 at 11:34 PM
$ALVO Alvotech is looking for more employees
0 · Reply
Latest News on ALVO
Alvotech Secures Term Loan Facility of USD 100 Million

Dec 31, 2025, 4:30 PM EST - 5 days ago

Alvotech Secures Term Loan Facility of USD 100 Million

Changes in company's own shares

Dec 29, 2025, 2:40 PM EST - 7 days ago

Changes in company's own shares

Alvotech's Financial Calendar for 2026

Dec 22, 2025, 3:26 PM EST - 14 days ago

Alvotech's Financial Calendar for 2026

Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma

Dec 22, 2025, 2:00 AM EST - 14 days ago

Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma

Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman

Dec 17, 2025, 4:08 PM EST - 19 days ago

Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman

Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering

Dec 17, 2025, 2:30 AM EST - 19 days ago

Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering

Alvotech (ALVO) Discusses Launch of $125 Million Commercial Bond Offering and Business Update Transcript

Dec 16, 2025, 3:19 PM EST - 20 days ago

Alvotech (ALVO) Discusses Launch of $125 Million Commercial Bond Offering and Business Update Transcript

Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area

Nov 24, 2025, 5:30 AM EST - 6 weeks ago

Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area

Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)

Nov 20, 2025, 4:00 AM EST - 6 weeks ago

Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)

Alvotech (ALVO) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 10:51 AM EST - 7 weeks ago

Alvotech (ALVO) Q3 2025 Earnings Call Transcript

Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update

Nov 12, 2025, 4:40 PM EST - 7 weeks ago

Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update

Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation into Alvotech (NASDAQ: ALVO)

Nov 10, 2025, 5:28 PM EST - 2 months ago

Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation into Alvotech (NASDAQ: ALVO)

Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation into Alvotech (NASDAQ: ALVO)

Nov 6, 2025, 6:28 PM EST - 2 months ago

Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation into Alvotech (NASDAQ: ALVO)

Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA

Nov 6, 2025, 9:07 AM EST - 2 months ago

Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA

Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update

Nov 4, 2025, 4:01 PM EST - 2 months ago

Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update

Alvotech Shares Plunge 33% After FDA Flags Issues

Nov 3, 2025, 1:17 PM EST - 2 months ago

Alvotech Shares Plunge 33% After FDA Flags Issues

Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05

Nov 2, 2025, 5:12 PM EST - 2 months ago

Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05

Alvotech Announces Changes in Global Business Development and Commercial Operations Team

Oct 22, 2025, 5:00 AM EDT - 2 months ago

Alvotech Announces Changes in Global Business Development and Commercial Operations Team

Alvotech: Promising Vertically Integrated Biosimilar Platform

Oct 15, 2025, 4:18 AM EDT - 2 months ago

Alvotech: Promising Vertically Integrated Biosimilar Platform

My Top 5 Biotech Stocks Big Pharma Could Buy Next

Oct 6, 2025, 1:29 PM EDT - 3 months ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ABBV AMGN ARKG AZN BIIB BMY GILD

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency

Oct 6, 2025, 4:40 AM EDT - 3 months ago

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency

European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva®

Sep 22, 2025, 6:15 AM EDT - 3 months ago

European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva®

European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner

Sep 22, 2025, 4:30 AM EDT - 3 months ago

European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner

Alvotech Announces Marketing Approval in Japan of Three New Biosimilars

Sep 19, 2025, 7:45 AM EDT - 3 months ago

Alvotech Announces Marketing Approval in Japan of Three New Biosimilars

Alvotech (ALVO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 1:28 PM EDT - 4 months ago

Alvotech (ALVO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York

Sep 4, 2025, 9:15 AM EDT - 4 months ago

Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York

Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®

Aug 21, 2025, 4:30 AM EDT - 4 months ago

Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®

Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia

Aug 20, 2025, 6:05 AM EDT - 4 months ago

Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia

Alvotech (ALVO) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 11:38 AM EDT - 5 months ago

Alvotech (ALVO) Q2 2025 Earnings Call Transcript

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

Aug 13, 2025, 4:15 PM EDT - 5 months ago

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

Aug 13, 2025, 4:15 PM EDT - 5 months ago

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT

Aug 6, 2025, 8:00 AM EDT - 5 months ago

Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT

Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer

Jul 10, 2025, 4:40 AM EDT - 6 months ago

Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee Group in Switzerland

Jul 9, 2025, 4:30 AM EDT - 6 months ago

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee Group in Switzerland

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland

Jul 9, 2025, 4:30 AM EDT - 6 months ago

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland

Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers

Jul 3, 2025, 7:02 PM EDT - 6 months ago

Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers

Granting of Stock Options and Vesting of Restricted Share Units

Jul 1, 2025, 7:54 PM EDT - 6 months ago

Granting of Stock Options and Vesting of Restricted Share Units

Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)

Jul 1, 2025, 4:00 AM EDT - 6 months ago

Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)

Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility

Jun 26, 2025, 4:15 AM EDT - 6 months ago

Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility

Main Results of 2025 Annual and Extraordinary General Meeting

Jun 25, 2025, 4:45 PM EDT - 6 months ago

Main Results of 2025 Annual and Extraordinary General Meeting

Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)

Jun 25, 2025, 4:00 AM EDT - 6 months ago

Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)

Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)

Jun 25, 2025, 4:00 AM EDT - 6 months ago

Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)

European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea® (aflibercept)

Jun 23, 2025, 4:00 AM EDT - 7 months ago

European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea® (aflibercept)

European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea® (aflibercept)

Jun 23, 2025, 4:00 AM EDT - 7 months ago

European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea® (aflibercept)

LIKEAG6
LIKEAG6 Jan. 3 at 1:37 AM
$ALVO Does anybody here know what this means? https://ml-eu.globenewswire.com/Resource/Download/1fef1de4-9efb-4061-90cf-24118cf4c963
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 31 at 8:32 PM
$ALVO RSI: 41.78, MACD: -0.1703 Vol: 0.31, MA20: 5.18, MA50: 5.71 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
GoldenStripe
GoldenStripe Dec. 30 at 2:46 AM
$ALVO
1 · Reply
scholar9
scholar9 Dec. 26 at 1:47 PM
$AMZN premarket quick take — volume > price $AMZN is trading around $232.1–232.4 premarket with ~200K matched premarket shares (30-day avg premarket vol ~674K). Today’s premarket volume is materially below average, so price moves lack strong conviction. Price sits above the 50-day MA (~$229) → medium-term bias still mildly bullish but unconfirmed. Trade note: wait for opening-volume confirmation (first 5–30 minutes) before chasing a breakout. Short-term support ~$229 (50-day MA); major support ~$216 (200-day MA). Watch ~$235 for a volume-confirmed near-term breakout; long-term resistance sits at the 52-wk high $258.60.with notice👉@scholar9 $AAOI $RCAT $DPRO $ALVO (Info/TA only — not financial advice)
0 · Reply
IntelligenceInsider
IntelligenceInsider Dec. 26 at 1:33 PM
$ALVO Risk appetite is present but conditioned on validation. Governance alignment should reduce uncertainty over time. Risk compresses once delivery patterns become predictable. Upside remains tied to tangible progress, not assumptions.
0 · Reply
briefingcom
briefingcom Dec. 19 at 1:30 PM
$ALVO: Alvotech and $TEVA secure U.S. settlement date for AVT06, a proposed biosimilar to Eylea https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20251219050530ALVO&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
Wences
Wences Dec. 18 at 2:09 PM
$ALVO Wessman has killed the stock with the bond offering.
1 · Reply
www_larval_com
www_larval_com Dec. 16 at 5:12 PM
Lookie here $ALVO has shot 9% higher to 0% (~600Kv) moments ago, follow for more volatility.
0 · Reply
JarvisFlow
JarvisFlow Dec. 9 at 3:15 PM
Barclays updates rating for Alvotech ( $ALVO ) to Underweight, target set at 5.
1 · Reply
Muhammediceland
Muhammediceland Dec. 8 at 11:34 PM
$ALVO Alvotech is looking for more employees
0 · Reply
Granger4783
Granger4783 Dec. 4 at 10:43 PM
$ALVO i think i stick around for a while :) long
0 · Reply
Muhammediceland
Muhammediceland Dec. 4 at 5:15 PM
$LCID While mostly talking about Lucid, I have +20 more stocks in my portfolio. And oh man oh man. I sold all my profiting $CBLL shares and put them in $ALVO . Alvotech literally has its headquarter around 100 meters from my PhD desk. Brand new building and you can see right through the windows; all the sophisticated stuff they are doing - or at least some of it haha. Already big profit... Let's go!
1 · Reply
Spytime
Spytime Dec. 3 at 2:39 PM
$ALVO Adding more short position today. Technical drop deep. Do it bear.
1 · Reply
Spytime
Spytime Dec. 3 at 12:37 PM
$ALVO another great day is coming. Keep selling all day long.
0 · Reply
Spytime
Spytime Dec. 2 at 9:10 PM
$ALVO Let's go Bear. Keep shorting this daily. Price is not low yet.
1 · Reply
mikesterz7
mikesterz7 Nov. 24 at 12:20 PM
$ALVO 🚨 AVT03 will be commercialised in Europe in partnerships with STADA Arzneimittel AG and Dr. Reddy’s, the company said.
0 · Reply
StocktwitsNews
StocktwitsNews Nov. 24 at 11:56 AM
Alvotech’s Drug Approved In Europe As Biosimilar For Bone Disease Drug $ALVO $IBBQ $PRFZ https://stocktwits.com/news/equity/markets/alvotech-drug-approved-in-europe-as-biosimilar-for-bone-disease-drugs/cL5bIelREQc
0 · Reply
nopeZ3
nopeZ3 Nov. 24 at 11:10 AM
$ALVO In at 5.14
0 · Reply
G101SPM
G101SPM Nov. 24 at 11:00 AM
$ALVO $5.14 ask. BUY/NEW LONG POSITION carries SPM 86.45 tag to $12.50 in long term (18 months).
0 · Reply
mru01
mru01 Nov. 24 at 10:57 AM
$ALVO great news!
0 · Reply
islandpunk
islandpunk Nov. 24 at 10:57 AM
$ALVO trending #5. let's go.
0 · Reply
islandpunk
islandpunk Nov. 24 at 10:34 AM
$ALVO Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area https://www.stocktitan.net/news/ALVO/alvotech-announces-approval-of-avt03-a-biosimilar-to-prolia-and-ksdimzmoqfjy.html
0 · Reply